IPP Bureau
Granules to donate 16 crores Paracetamol tablets to Telangana
By IPP Bureau - May 15, 2021
The company will provide one crore tablets every week, starting from 12th May 2021, aggregating to 16 crore tablets worth Rs. 8 crores over the next 4 months
Gap between two doses of Covishield extended; No extension for Covaxin
By IPP Bureau - May 14, 2021
The COVID Working Group has recommended extension of the gap between the first and second doses of Covishield
Govt. to allow 100% doses of imported and ready to use foreign vaccine
By IPP Bureau - May 14, 2021
Proactively engaging with foreign vaccine manufacturers like Moderna, Pfizer etc., to apply for Emergency Use Authorization in India so that these vaccines can be easily imported and made available in India
Zydus Cadila entity to sell its India focused animal health business to a consortium
By IPP Bureau - May 13, 2021
The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
Eris Lifesciences reports Q4FY21 consolidated net profit of Rs. 68.24 Cr
By IPP Bureau - May 13, 2021
Eris Lifesciences has reported total income of Rs.1220.57 crores during the 12 months period ended March 31, 2021
COVAXIN phase II/III clinical trial approved for 2-18 years
By IPP Bureau - May 13, 2021
BBIL had proposed to carry out Phase II/III clinical trial of Covaxin in the age group of 2 to 18 years
Torrent Pharma enters into agreement with Lilly for Baricitinib for Covid-19 in India
By IPP Bureau - May 13, 2021
The agreement will help ensure wider reach and access to patients in India
Lupin reports Q4FY21 consolidated PAT of Rs. 460.36 Cr
By IPP Bureau - May 13, 2021
It reported total income of Rs.15299.25 crores during the FY ended March 31, 2021
Additional Tocilizumab allocated to states: Gowda
By IPP Bureau - May 12, 2021
The additional allocation of Tocilizumab will ensure sufficient availability for COVID-19 patients and augment the government’s efforts to fight the pandemic
Dr. Reddy's launches Ertapenem in US
By IPP Bureau - May 12, 2021
The INVANZ brand and generic market had U.S. sales of approximately US $205 million MAT for the most recent twelve months ending March 2021 according to IQVIA Health
Govt. ramps up Amphotericin B manufacturing to fight Mucormycosis
By IPP Bureau - May 12, 2021
The Department of Pharma has allocated this drug amongst the states/UTs based on expected supply that will be available from May 10 to May 31, 2021
Brinton triples production of COVID-19 drug Favipiravir
By IPP Bureau - May 12, 2021
Favipiravir is close to Remdesivir, Remdesivir is used to treat moderate to severe cases while Favipiravir is used to treat mild to moderate cases
Vivimed Labs to manufacture, market Favipiravir tablets
By IPP Bureau - May 11, 2021
The tablets will be manufactured and marketed under Vivimed’s brand name “Favulous” across India
CRISIL assigns 'Positive' outlook to Jubilant Pharmova's long-term rating
By IPP Bureau - May 11, 2021
The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.
Alembic reports net profit of Rs. 71.94 Cr in Q4FY21
By IPP Bureau - May 11, 2021
Alembic has reported total income of Rs.83.79 crores during the FY ended March 31, 2021
